No Data
No Data
Longboard Pharmaceuticals Is Maintained at Buy by B. Riley Securities
Longboard Pharmaceuticals Is Maintained at Buy by B. Riley Securities
Express News | B. Riley Securities Maintains Buy on Longboard Pharmaceuticals, Raises Price Target to $36
H.C. Wainwright Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Maintains Target Price $60
H.C. Wainwright analyst Patrick Trucchio maintains $Longboard Pharmaceuticals(LBPH.US)$ with a buy rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success r
B. Riley Raises Price Target on Longboard Pharmaceuticals to $36 From $30, Maintains Buy Rating
Longboard Pharmaceuticals (LBPH) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $32 to $60.
Citi Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Maintains Target Price $40
Citi analyst David Hoang maintains $Longboard Pharmaceuticals(LBPH.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 35.3% and
Express News | Longboard Pharmaceuticals Inc : B. Riley Raises Target Price to $36 From $30
No Data
Raza Zaidi : Any chances of recovery?
JOKER555OP Raza Zaidi: 30%